Transdermal skin patches are self-contained, disposable patches that are placed on the skin to deliver a pre-determined dose of medication through the skin and into the bloodstream continuously over an extended period of time, typically from a few days to a week. Skin patches are used for the application of local anesthetics or agents for the management of chronic pain, hormone replacement therapy, nicotine replacement therapy, and neurology disorders.

The global therapeutic transdermal skin patches market is estimated to be valued at US$ 9773.27 Bn in 2023 and is expected to exhibit a CAGR of 23% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The growing geriatric population and the increasing prevalence of chronic and lifestyle diseases represents a major market opportunity for pain management through transdermal skin patches. Older adults are more prone to develop chronic pain due to age-related wear and tear as well as chronic conditions such as arthritis. With rising life expectancy and the burgeoning geriatric demographic, it is estimated that over 1.5 billion people aged 65 years and older will be affected by some form of pain globally by 2050. Transdermal patches provide a convenient, safe, and reliable method for the delivery of analgesic drugs to manage both acute and chronic pain. The Non-invasive nature of skin patches helps improve patient compliance especially in geriatric patients. This represents a significant opportunity for companies to expand their presence in the pain management segment through transdermal technologies.

Porter's Analysis
Threat of new entrants: The Transdermal Skin Patches market size has moderate threat of new entrants due to high capital requirement and established players. However, patent expiration of major drugs offers opportunities.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitutes and preference for cost-effective generic drugs.
Bargaining power of suppliers: raw material suppliers have low to moderate bargaining power due to availability of substitutes and presence of many suppliers.
Threat of new substitutes: Oral drugs pose moderate threat but transdermal patches offer better patient compliance and precision in dosage.
Competitive rivalry: The market has high competitive rivalry due to many global and local players offering generics.

SWOT Analysis
Strength: Precision in dosage control, better efficacy than oral drugs, improved patient compliance.
Weakness: High costs, issues related to drug permeability, stringent regulatory approvals.
Opportunity: Growing geriatric population prone to chronic diseases, patent expiration of blockbuster drugs.
Threats: Preference for inexpensive alternatives, entry of biosimilars.

Key Takeaways
The global Transdermal Skin Patches market is expected to witness high growth over the forecast period 2024-2031.

Regional analysis of Asia Pacific region indicates fastest growth over forecast period. Rising healthcare expenditure, growth in medical tourism and generics market, increasing awareness are factors augmenting the transdermal patches market in Asia Pacific region.

Key players operating in the Transdermal Skin Patches market are Omsk Carbon Group, Tokai Carbon Co., Ltd., Atlas Organics Private Limited, Continental Carbon Company, Birla Carbon, Cabot Corporation, International China Oak Investment Holdings Co., Ltd., Himadri Speciality Chemical Ltd, Philips Carbon Black Limited, Orion Engineered Carbons GmbH, Ralson.

Get more insights on this topic: https://www.pressreleasebulletin.com/therapeutic-transdermal-skin-patches-market-size-and-opportunity-analysis/

Explore more trending article on this topic: https://captionssky.com/threaded-elegance-weaving-stories-through-time-in-textile-and-apparel-craftsmanship/